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While genetic factors clearly play a role in conferring breast cancer risk, the contribution of ATM gene mutations to breast cancer is
still unsettled. To shed light on this issue, ATM haplotypes were constructed using eight SNPs spanning the ATM gene region (142kb)
in ethnically diverse non-Ashkenazi Jewish controls (n¼118) and high-risk (n¼142) women. Of the 28 haplotypes noted, four were
encountered in frequencies of 5% or more and accounted for 85% of all haplotypes. Subsequently, ATM haplotyping of high-risk,
non-Ashkenazi Jews was performed on 66 women with breast cancer and 76 asymptomatic. One SNP (rs228589) was significantly
more prevalent among breast cancer cases compared with controls (P¼4 10
 9), and one discriminative ATM haplotype was
significantly more prevalent among breast cancer cases (33.3%) compared with controls (3.8%), (Pp10
 10). There was no significant
difference in the SNP and haplotype distribution between asymptomatic high-risk and symptomatic women as a function of disease
status. We conclude that a specific ATM SNP and a specific haplotype are associated with increased breast cancer risk in high-risk
non-Ashkenazi Jews.
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Inherited predisposition to breast cancer is well established in
BRCA1 (MIM# 113705) and BRCA2 (MIM# 600185) mutation
carriers (reviewed by Narod and Foulkes, 2004). Yet, only 20–40%
of familial inherited breast cancer risk is conferred by BRCA1/2
mutations, and clearly other genes are involved in familial breast
cancer clustering (Ford et al, 1998; Nathanson and Weber, 2001;
Thompson and Easton, 2004; Garber and Offit, 2005). A strong
candidate for a breast cancer predisposition gene is ATM (MIM#
607585). The attribution of ATM candidacy as a breast cancer
susceptibility gene stems from two sources. Functionally, the ATM
protein is a pivotal player in mediating cellular responses to DNA
damage, including DNA double-strand break repair and signaling,
leading to cell-cycle arrest and apoptosis (reviewed in Rotman
and Shiloh, 1999). From the genetic perspective, ATM is the gene
mutated in ataxia-telangiectasia (AT), an autosomal recessive
disorder phenotypically characterised by chromosomal instability
and an increased risk for lymphoproliferative tumors in homo-
zygotes (Swift et al, 1991; Gatti et al, 1999). Ataxia-telangiectasia
heterozygotes that are asymptomatic have been reported to be at
an increased risk for developing breast cancer (Swift et al, 1991;
Gatti et al, 1999; reviewed by Hall, 2005), although these reports
are still controversial and not universally accepted. ATM gene’s
contribution to breast cancer risk was previously evaluated in the
context of high-risk families, in BRCA1/2 mutation carriers, and in
average risk populations (reviewed in Gatti et al, 1999; Hall, 2005).
The results of these studies are inconclusive, with some studies
reporting an increased breast cancer risk (Swift et al, 1987; Pippard
et al, 1988; Athma et al, 1996; Stancovic et al, 1998; Inskip et al,
1999; Janin et al, 1999) and others failing to demonstrate such an
effect in heterozygote ATM mutation carriers (Vorechovsky et al,
1996; FitzGerald et al, 1997; Bay et al, 1998; Chen et al, 1998).
In order to shed further light on the putative contribution of
ATM to breast cancer risk, we performed haplotyping of the ATM
locus in high-risk individuals and controls of non-Ashkenazi
Jewish origin.
MATERIALS AND METHODS
High-risk participants: identification, recruitment, and
data collection
All high-risk individuals studied herein were ascertained and
identified from among individuals referred for genetic counseling
and testing at the Oncogenetics unit, Sheba Medical Center, Tel
Hashomer Israel. Only one individual per high-risk family was
included in the study. All participants were counseled for family
history of breast cancer, and all affected women had histopatho-
logically proven breast cancer. Relevant demographic and clinical
data were collected at the time of initial genetic counseling and
included type of malignancy (based on pathology reports), age
at diagnosis, age at counseling, and ethnic origin at least three
generations back. High risk was assigned based on current
accepted criteria (Lynch and Lynch, 2002). The study was
approved by the institutional review board (Helsinki committees)
at Sheba Medical Center, and each participant signed a written
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sinformed consent. Based on the results of the genetic testing (see
below), none of the study participants was a carrier of any of the
predominant Jewish mutations in BRCA1/2.
Control population
DNA samples were taken from unrelated, healthy, non-Ashkenazi
individuals, with no personal or familial history of cancer. These
were recruited primarily from among women who escorted the
high-risk women but were unrelated to them (e.g. friends, married
ins, etc.). All study participants among controls gave their consent
for anonymous testing.
Origin of patients
All the patients in this study are non-Ashkenazi Jews originating
from Iraq, the Balkan, and Yemen.
DNA isolation
Genomic DNA was prepared from anticoagulated, venous blood
samples using the PUREGene DNA isolation kit (Gentra systems
Inc., Minneapolis, MN, USA) using the manufacturer’s recom-
mended protocol.
Genotyping for the recurring BRCA1/BRCA2 mutations
None of the (high risk and control) participants of this study
carried any of the four recurring BRCA1 (185delAG, 5382InsC,
Tyr978X) and BRCA2 (6174delT) mutations reported in Jewish
individuals. Detection of these mutations was carried out by
modified restriction enzyme digest assay, which distinguishes the
mutant from the wild-type allele, using primer sequences, cycling
profiles, PCR conditions, and gel electrophoresis as previously
described (Rohlfs et al, 1997; Shiri-Sverdlov et al, 2001). Only
individuals not carrying these mutations were included in the
subsequent study.
ATM SNP selection and genotyping
ATM genotyping was performed by PCR amplification of eight
SNPs throughout the gene. The SNPs were chosen from three
databases: www.ensembl.org www.genome.ucsc.edu and
www.ncbi.nlm.nih.gov. The SNPs genotyped were ss4328153
(now rs3092993), rs228589, rs600931, rs664677, rs227069,
rs664982, rs652541, and rs170548 (Table 1). SNP genotyping was
carried out using the Sequenomt MASSarray system (Sequenom,
San-Diego, CA, USA).
Sequenomt MassARRAY system
PCR amplification was performed in 384-well microplates (Marsh
Biomedical Products, Rochester, NY, USA), in a total volume of
5ml, using 2.5ngreaction
 1 DNA, 10  PCR Buffer containing
1.5mM MgCl2, 200mM dNTPs mix, 0.02ml HotStar Taq Polymerase
at 5Uml
 1 (Qiagen Inc., Valencia, CA, USA), and 1pmol each of
forward and reverse PCR primer. After an initial denaturation at
941C for 5min, 45 cycles of 941C for 20s, annealing at 561C for 30s,
and extension at 721C for 1min were carried out with a final
extension period of 3min. Primer sequences, designed using the
software SpectroDESIGNER (Sequenom, San-Diego, CA, USA), are
shown in Table 2.
PCR amplification was performed in multiplex reactions as
follows:
Multiplex 1: SNPrs228589þSNPrs3092993þSNPrs170548.
Multiplex 2: SNPrs652541þSNPrs227069þSNPrs664982.
Multiplex 3: SNPrs664677þSNPrs600931.
Following PCR, SNP genotyping proceeded as previously
described (Little et al, 1997a,b; Buetow et al, 2001).
Similar to these above-mentioned studies, quality control and
quality assurance were provided by randomly including non-DNA
containing well in the chip as well as re-genotyping about 10% of
the samples for all SNPs on different chips.
Table 1 ATM SNPs
a
SNP no. SNP ID Position
b Polymorphism Minor allele frequency
1 rs3092993
c 11797531 A/C 0.068
2 rs228589 11655624 A/T 0.144
3 rs600931 11679751 A/G 0.236
4 rs664677 11705598 C/T 0.242
5 rs227069 11772674 A/G 0.272
6 rs664982 11787899 A/G 0.24
7 rs652541 11788441 C/T 0.155
8 rs170548 11797252 G/T 0.342
aAll SNPs are intronic and noncoding.
bPosition based on Genbank Accession
Number NT_033899 (http://www.ncbi.nih.gov/entrez/query.fcgi?db¼snp&cmd¼
search&term¼rs).
cThis SNP was originally coined ss4328153.
Table 2 Primer sequences used for detecting the relevant SNPs
SNP Forward, reverse primers Extension primer
1 F: ACGTTGGATGGTTAGCTGTTCTGAACTGCC E: GAACTGCCAATATCAGAAATTC
R: ACGTTGGATGGAGCAAGTAGCTTTAGGTCG
2 F: ACGTTGGATGTTTGGCCTCAAAGGTCCTTC E: GGGTCCAATAACCCTCC
R: ACGTTGGATGCTTGTATTGGGTAAGCGCGG
3 F: ACGTTGGATGCTCCGTATGCCTTTTTCTGG E: TCTGGCCTAAGAGAAAAATATTAC
R: ACGTTGGATGCTGAAATGGTGAGAAGTCTG
4 F: ACGTTGGATGAGCACTCAGAAAACTCACTG E: AAAACTCACTGAAAGGTTATT
R: ACGTTGGATGGAGTATGTTGGCATATTCCAC
5 F: ACGTTGGATGGCTGTGTACTTTCAGAGAAC E: TCAGTCCTTTTTTGTGG
R: ACGTTGGATGCTGGGTATCTGGGTATTTTG
6 F: ACGTTGGATGCAGCATACTACACATGAGAG E: CATGAGAGTATACAGATAAAGATA
R: ACGTTGGATGCAGCATCTAGAGTCAAACAC
7 F: ACGTTGGATGAGGTAGCACCAGCAGTAAAC E: CCCTCATTCCTAAGCCA
R: ACGTTGGATGGGAGATCAAATTGTCAGCATC
8 F: ACGTTGGATGTTAATGGTCCTGGAGGACAC E: CAAAACAGCATTAAAAAATAGAG
R: ACGTTGGATGAGGACACGTACTAGATTAGC
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association analyses
The process of phasing the genotypes and imputing the missing data
was performed by the software GERBIL (Kimmel and Shamir, 2005).
The association between sequence variants and breast cancer
was evaluated by permutation test (Zhang et al, 2002) as follows: to
evaluate the overall P-value of the association between the SNPs
genotypes and the disease, the Pearson score of each marker is
calculated, and the maximum value over all markers, denoted
CCmax, is chosen as the test statistic. Then, the same statistic is
calculated for many data sets with the same genotypes and
randomly permuted labels of the case and control individuals. The
fraction of times that this value exceeds CCmax is used as the
P-value. This test has the advantage of not assuming a specific
distribution function. Additionally, it handles multiple-testing
directly and avoids the bias of correction, for example, by the over-
conservative Bonferroni method. This test was applied to cases vs
controls, and also to the high-risk group vs controls.
Since there are three different population groups in the study,
originating from Iraq, the Balkan and Yemen, the score for each
marker was calculated as follows: Let Pi,j be the Pearson score of
the jth marker for the ith population (out of three possibilities).
The statistic CCPmax is defined to be maxj
P
iPi,j. The P-value is
calculated by a permutation test as mentioned above, with the
difference of randomly permuting the labels within each popula-
tion independently, and using the statistic CCPmax instead of
CCmax. This statistic avoids the bias in the P-value that might occur
due to the mixture of different populations.
The permutation test can be readily generalised to handle
association between haplotypes and the disease, for example, by
adding block haplotypes as artificial loci with states corresponding
to common haplotypes. Similarly, one can add loci interactions as
artificial loci, whose states are the allele combinations.
Estimates of odds ratio (OR), relative risk (RR), and 95%
confidence interval (CI) were calculated for the discriminative
SNPs and haplotypes (Tables 3A and B).
We repeated the above procedure to perform two different tests:
(1) Association test for each SNP separately and for the haplotype
composed from all the eight SNPs.
(2) Association test of all possible pair-wise interactions
of SNPs.
RESULTS
Characteristics of study participants
In total, 260 unrelated women of non-Ashkenazi Jewish origin
were genotyped in this study. Of these, 142 were evaluated and
considered at high risk for developing breast cancer based on their
family history. Of the high-risk individuals, 66 (46.5%) were breast
cancer cases (mean age at diagnosis was 48.379.7 years) and their
ethnic origin was Iraqi (n¼34 or 51.5%), Balkan (n¼16 or
24.25%), or Yemenite origin (n¼16 or 24.25%). Additional 76
(53.5%) women were asymptomatic, high-risk women. The age
range at counseling for the high-risk asymptomatic group was
28–67 years (mean 50.3710.5 years), and their ethnic distribution
was as follows: 34 of Iraqi (44.7%), 26 of Balkan (34.2%), and 16 of
Yemenite origin (21%). The ethnicity of the population-matched
healthy controls (n¼118) was 55 (46.61%) Iraqis, 29 (24.57%) of
Balkan origin, and 34 (28.81%) Yemenites. The age range at
counseling for the control group was 33–69 years (mean 53.478.9
years).
All participants were genetically prescreened and shown not
carry any of the four common Jewish mutations in BRCA1
(185delAG; 5382insC; Tyr978X) and in BRCA2 (6174delT).
Phasing the genotypes
Phasing the genotypes of the eight SNPs at the ATM locus yielded
together 28 different haplotypes in one block of high LD (Table 4).
Four haplotypes had a frequency X0.05 (Table 5A) accounting
together for 85% of all haplotypes. For association test of the
haplotypes, we generated four clusters corresponding to the four
common haplotypes and clustered each rare haplotype with the
common haplotype to which it resembled most, as measured by
Hamming distance.
Association tests
We first compared the breast cancer patients to the control
population. SNP 2 (rs228589) is the most associated with the
disease, with score of 61.61 (after multiple testing correction:
P¼4 10
 9). In this SNP, nucleotide T appears in 3.8% of the
controls and in 33.3% of the cases (Table 3A). Odds ratios and RR
values for this SNP are listed in Table 3B.
An association test was performed for each SNP separately and
for the complete 8-SNP haplotype. The Pearson scores of
association are presented in Table 6. Interestingly, this SNP alone
Table 3A Frequencies of the most associated SNP (number 2,
rs228589)
Allele Frequency
Case
(n¼66) %
Healthy high
risk (n¼76) %
Control
(n¼118) %
A 0.856 66.7 51.4 96.2
T 0.144 33.3 48.6 3.8
Table 3B Comparison of the most associated SNP (number 2, rs228589) between the study’s subgroups: case vs control, and asymptomatic high-risk vs
control
Alleles (%) RR (95% CI) OR (95% CI)
Study subset A T A T A T
Breast cancer case vs control 88 (67) 44 (33) 0.34 (0.27–0.42) 2.97 (2.4–3.69) 0.08 (0.04–0.17) 12.61 (5.91–26.92)
227 (96) 9 (4)
Asymptomatic high risk vs control 76 (51) 72 (49) 0.28 (0.23–0.35) 3.45 (2.87–4.37) 0.04 (0.02–0.09) 23.89 (11.4–50.08)
227 (96) 9 (4)
All high-risk women vs control 303 (79) 81 (21) 0.45 (0.4–0.51) 2.21 (1.95–2.51) 0.06 (0.03–0.11) 17.84 (8.79–36.19)
227 (96) 9 (4)
RR, relative risk; OR, odds ratio; CI, confidence interval.
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31.45).
An additional test was performed for each pair of SNPs. The pair
of SNPs most associated was SNP 1 (rs3092993) and 2 (rs228589)
(both intronic SNPs) (Pp10
 10). We therefore examined the short
genotypes consisting of SNP 1 and SNP 2. These genotypes form
three common haplotypes, coined A, B and C (Table 5B), and
additional rare haplotype of frequency 0.002, which we ignored for
the association test. Haplotypes B and C were significantly more
prevalent in cases (33.3%) compared with controls (3.8%): odd
ratios and RR values for these two haplotypes are listed in
Table 7A. In agreement with the above, these two haplotypes were
also significantly more prevalent in the healthy high risk (24.3 and
14.5%) compared with controls (3.8% and 4.7%). In contrast,
haplotype A was significantly more prevalent in controls (91.5%)
as compared to cases (56%) or healthy high risk (61.2%). Odd
ratios and RRs followed compatible trends (Table 7A).
Next, we tested all case and high-risk patients clustered together
as a single group vs controls. When testing each SNP separately,
the most associated SNP is again SNP 2 (rs228589) (P¼7 10
 9).
When testing all pairwise interactions of SNPs, the most associated
pair is SNP 2 (rs228589) and SNP 3 (rs600931) (Pp10
 9)
Table 4 The LD scores (measured in r
2) between all 8 SNPs
12345678
1  1 0.01 0.02 0.02 0.17 0.02 0.01 0.12
2 0.01  1 0.49 0.50 0.41 0.51 0.88 0.17
3 0.02 0.49  1 0.88 0.32 0.93 0.54 0.18
4 0.02 0.50 0.88  1 0.29 0.87 0.57 0.19
5 0.17 0.41 0.32 0.29  1 0.33 0.47 0.46
6 0.02 0.51 0.93 0.87 0.33  1 0.58 0.19
7 0.01 0.88 0.54 0.57 0.47 0.58  1 0.20
8 0.12 0.18 0.18 0.19 0.46 0.19 0.20  1
Table 5A The inferred haplotypes and their frequency
Haplotype Frequency Haplotype sequence
1 0.553 C A A T G A C G
2 0.130 C T G C A G T T
3 0.086 A A A T A A C T
4 0.075 C A A T G A C T
5 0.032 C T G C A G T G
6 0.025 C A G C G G C G
7 0.017 C A A T A A C T
8 0.017 C A G C G G C T
9 0.008 C A G C A G C T
10 0.008 C A A T A A C G
11 0.008 C A G C A G T T
12 0.004 C A G T A G C T
13 0.004 C A A T G G C G
14 0.004 C A G C G A C G
15 0.002 C A A C A A C T
16 0.002 C T G T A G C T
17 0.002 C A A C G A C G
18 0.002 C A G C A G C G
19 0.002 A A A T G A C G
20 0.002 A T A C A G T T
21 0.002 C T G C A G C G
22 0.002 C A A T G G C T
23 0.002 C A A C G A C T
24 0.002 C A G T A G C G
25 0.002 A A A T A A C G
26 0.002 C A A C A G T T
27 0.002 C T A T G A C T
28 0.002 C T A C G G T T
Haplotypes that have frequency X5% are indicated in bold.
Table 5B Frequencies of the haplotypes composed of SNPs 1 and 2
Haplotype
Haplotype
sequence Frequency
Case
(n¼66)
%
Healthy
high risk
(n¼76) %
Control
(n¼118)
%
A CA 0.737 56 61.2 91.5
B CT 0.171 33.3 24.3 3.8
C AA 0.09 10.6 14.5 4.7
Table 5C Frequencies of the haplotypes composed of SNPs 2 and 3
Haplotype
Haplotype
sequence Frequency
Healthy
high risk+case
(n¼142) %
Control
(n¼118) %
D AA 0.763 72.5 80.9
E TG 0.167 27.5 3.8
F AG 0.069 0 15.3
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this test. One short haplotype consisting of SNPs 2 and 3, coined E
(Table 7B) confers a RR of 7.2 95% CI (3.69–14.05), and an OR of
9.55 95% CI (4.67–19.5).
Testing association of the individual SNPs and of all the SNP
pairs on the group of high-risk women vs cases yields no
significant result (P¼0.35).
DISCUSSION
In this study, several ATM SNPs were seemingly associated with
breast cancer risk in Jewish non-Ashkenazi women at high-risk for
breast cancer. These results further establish ATM as a contributor
to breast cancer susceptibility in high-risk populations.
Increased breast cancer risk in ATM heterozygote mutation
carriers has been previously reported in studies that either inferred
obligate carriership (Swift et al, 1987; Pippard et al, 1988) or
directly tested for gene mutations (Athma et al, 1996; Stancovic
et al, 1998; Inskip et al, 1999; Janin et al, 1999; Olsen et al, 2001).
Epidemiological studies have consistently shown that female
relatives of A-T patients are at an increased risk for developing
breast cancer (reviewed in Hall, 2005). Interestingly, this increased
risk was predominantly observed in the mothers of A-T carriers
and not in siblings and offsprings (Olsen et al, 2005). Yet, not all
studies confirmed the associated breast cancer risk conferred by
being an ATM heterozygous mutation carrier (Vorechovsky et al,
1996; FitzGerald et al, 1997; Bay et al, 1998; Chen et al, 1998).
Two ATM germline alterations (Ala2524Pro and 6903insA)
reported in A-T families have been shown to segregate with breast
cancer in these families (Laake et al, 2000). Stancovic et al (1998)
described two additional A-T families, where a heterozygous
missense mutation, Val2424Gly (7271ToG) was associated with a
presumed increased breast cancer risk. Another ATM mutation
(IVS10-6ToG) was suggested to be associated with early-onset
breast cancer risk in patients, who were exposed to low-dose
ionising radiation (Broeks et al, 2000; Do ¨rk et al, 2001). The latter
two mutations were functionally shown to exert a dominant
negative effect on ATM protein (Chenevix-Trench et al, 2002). The
contribution of the Val2424Gly and the IVS10-6ToG mutations
to increased breast cancer risk was further established in a large
population-based, case–control study (Chenevix-Trench et al,
2002).
As most studies focused on sporadic rather than familial breast
cancer cases, and employed screening methods preferentially
capable of detecting protein-truncating mutations (A ´ngele and
Hall, 2000), there might be more ATM non-truncating mutations
and/or polymorphisms or variants (e.g. missense mutations) that
affect breast cancer risk. In support of this notion, ATM missense
substitutions seem to be more prevalent among Swedish, Canadian
and Slovenian breast cancer patients (Do ¨rk et al, 2001) and among
US heterogeneous women (Teraoka et al, 2001). These findings
give credence to the hypothesis that there are two distinct
populations of ATM heterozygous mutations: null mutations or
truncating mutations are not associated with breast cancer risk,
whereas the presence of even a single missense allele may have a
dominant negative effect on protein function and thus be
associated with breast cancer risk (Meyn, 1999; Khanna, 2000).
However, a more recent study from the UK (Thompson et al, 2005)
shows that while being an ATM heterozygote does contribute to a
modest increase in breast cancer risk, there are no differences in
the risk as a function of mutation type.
The majority of studies conducted to assess ATM’s contribution
to breast cancer have used a variety of mutation detection
techniques, with predominant bias for the detection of protein
truncating mutations, or else they have examined the effect of
specific ATM variants that are prevalent in the studied population
(Hall, 2005). Only a handful of studies have used haplotyping, a
mutation independent method, to assess the effect of ATM on
breast cancer risk. Angele et al (2003) report that of the three
major ATM haplotypes, one was significantly associated with
breast cancer risk in French women. Similar results were also
reported from Korea (Lee et al, 2005). Conversely, Tamimi et al
(2004) used a large collection of cases and controls (more than
1300 individuals in each group) from the Nurses Health study, and
Table 7 Comparison of the short haplotypes between the study’s subgroups: (A) case vs control, and asymptomatic high-risk vs control (Table 5B) and
(B) all high-risk vs control (Table 5C)
Haplotypes (%) RR (95% CI) OR (95% CI)
Study subset A B C A B C A B C
(A)
Breast cancer case 74 (56) 44 (33) 14 (0.6) 0.61 (0.49–0.76) 8.74(3.32–23.02) 2.28 (0.78–6.67) 0.12(0.05–0.27) 12.61(4.32–36.84) 2.43(0.76–7.74)
Vs control 216 (91) 9 (4) 11 (4.6)
Asymptomatic high risk 93 (61) 37 (24) 22 (14.5) 0.66 (0.55–0.81) 6.38 (2.37–17.16) 3.11(1.16–8.29) 0.146 (0.07–0.32) 8.115 (2.76–23.85) 3.461 (1.19–10.07)
Vs control 216 (91) 9 (4) 11 (4.6)
(B)
Haplotypes (%) RR (95% CI) OR (95% CI)
Study subset D E F D E F D E F
All high-risk women 206 (73) 78 (27) 0 (0) 0.9 (0.82–0.99) 7.2 (3.69–14.05) — 0.62 (0.41–0.94) 9.55 (4.67–19.5) —
Vs control 191 (81) 9 (4) 36 (15)
RR, relative risk; OR, odds ratio; CI, confidence interval.
Table 6 Pearson scores for association of the individual SNPs and of the
haplotype to the disease phenotype
SNP Score
1 8.13
2 61.61
3 12.23
4 11.39
5 26.14
6 12.16
7 51.97
8 11.88
Haplotype 31.46
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with breast cancer risk in American women.
The current study is the first to report ATM SNP and haplotype
in a population of high-risk non-Ashkenazi Jewish women. Unlike
the lack of a discriminating ATM haplotype among average risk
Ashkenazi Jewish breast cancer women (Bonnen et al, 2001), the
present study shows that ATM does contribute to familial
clustering of breast cancer in non-Ashkenazim. It is noteworthy
that specific genotypes are associated with breast cancer risk even
without performing the phasing process. A very strong association
(P¼4 10
 9) was noted by testing each SNP separately, and
correcting for multiple hypotheses using permutation tests. Given
the intronic position of the two SNPs most tightly associated with
breast cancer risk and phenotype, it is unlikely that these SNPs in
and by themselves are disease associated. Rather, in all likelihood
they are in linkage disequilibrium with a pathogenic ATM
mutation.
It is important to emphasise that only one patient was analyzed
per high-risk family, so that patients in the high-risk group are not
more genetically related to each other than in the control group.
Additionally, our statistical method for computing the P-value
takes into account the three different subpopulations and corrects
for multiple testing. Hence, the strong association noted between
the ATM genotype and the high-risk phenotype seems real, and
cannot be accounted for as an artifact caused by analysis of related
individuals.
The limitations of the study should be pointed out. This was a
relatively small study that analyzed a highly selected population,
and includes only non-Ashkenazi Jewish women who were
recruited through high-risk clinic in a single medical center in
Israel. Thus, the applicability of the results to average-risk
population or even high risk, ethnically diverse populations, needs
to be established.
In conclusion, the present study suggests that a specific ATM
SNP seemingly contributes to breast cancer predisposition in
Jewish non-Ashkenazi high-risk women in Israel.
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